There were 707 press releases posted in the last 24 hours and 467,819 in the last 365 days.

DEADLINE TOMORROW: The Law Offices of Vincent Wong Reminds Investors of a Class Action Lawsuit Involving Lipocine Inc. and a Lead Plaintiff Deadline of August 30, 2016 - LPCN

NEW YORK, Aug. 29, 2016 (GLOBE NEWSWIRE) -- The Law Offices of Vincent Wong announce that a class action lawsuit has been commenced in the USDC for the District of New Jersey on behalf of investors who purchased Lipocine Inc. (NASDAQ:LPCN) securities between June 30, 2015 and June 28, 2016.

Click here to learn about the case: There is no cost or obligation to you.

According to the complaint, throughout the Class Period, defendants issued materially false and/or misleading statements and/or failed to disclose that: (1) Lipocine’s filing of its New Drug Application for LPCN 1021, Lipocine’s lead product candidate, contained deficiencies; and (2) as a result, defendant’s statements about Lipocine’s business and operations were false and misleading and/or lacked a reasonable basis.

On June 29, 2016, Lipocine announced that the U.S. Food and Drug Administration had issued a Complete Response Letter regarding the Company’s New Drug Application for LPCN 1021. According to the Complete Response Letter, the FDA has identified deficiencies related to the dosing algorithm for the label and concluded the application was not ready for approval in its present form.

If you suffered a loss in Lipocine you have until August 30, 2016 to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn’t require that you serve as a lead plaintiff. To obtain additional information, contact Vincent Wong, Esq. either via email, by telephone at 212.425.1140, or visit

Vincent Wong, Esq. is an experienced attorney that has represented investors in securities litigations involving financial fraud and violations of shareholder rights.  Attorney advertising. Prior results do not guarantee similar outcomes.

Vincent Wong, Esq.
39 East Broadway
Suite 304
New York, NY 10002
Tel. 212.425.1140
Fax. 866.699.3880

Primary Logo